Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBITDA: 2023-2025

Historic EBITDA for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$27.0 million.

  • Monte Rosa Therapeutics' EBITDA fell 14.65% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 116.65%. This contributed to the annual value of -$73.3 million for FY2024, which is 46.21% up from last year.
  • Monte Rosa Therapeutics' EBITDA amounted to -$27.0 million in Q3 2025, which was down 118.45% from -$12.3 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' EBITDA ranged from a high of $46.9 million in Q1 2025 and a low of -$35.4 million during Q2 2023.
  • Its 3-year average for EBITDA is -$18.4 million, with a median of -$30.3 million in 2024.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' EBITDA showed a top increase of 246.89% in 2025 and a maximum decrease of 14.65% in 2025.
  • Monte Rosa Therapeutics' EBITDA (Quarterly) stood at -$34.5 million in 2023, then soared by 135.93% to $12.4 million in 2024, then dropped by 14.65% to -$27.0 million in 2025.
  • Its EBITDA stands at -$27.0 million for Q3 2025, versus -$12.3 million for Q2 2025 and $46.9 million for Q1 2025.